315 related articles for article (PubMed ID: 15776390)
1. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
2. Antimalarial effects of HIV proteinase inhibitors: common compounds but structurally distinct enzymes.
Wyatt DM; Berry C
J Infect Dis; 2005 Aug; 192(4):705-6. PubMed ID: 16028143
[No Abstract] [Full Text] [Related]
3. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
4. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
5. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
6. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
8. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
9. Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
Boss C; Corminboeuf O; Grisostomi C; Meyer S; Jones AF; Prade L; Binkert C; Fischli W; Weller T; Bur D
ChemMedChem; 2006 Dec; 1(12):1341-5. PubMed ID: 17091526
[No Abstract] [Full Text] [Related]
10. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
11. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function.
Bonilla JA; Bonilla TD; Yowell CA; Fujioka H; Dame JB
Mol Microbiol; 2007 Jul; 65(1):64-75. PubMed ID: 17581121
[TBL] [Abstract][Full Text] [Related]
12. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
13. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
[TBL] [Abstract][Full Text] [Related]
15. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
Parikh S; Gut J; Istvan E; Goldberg DE; Havlir DV; Rosenthal PJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2983-5. PubMed ID: 15980379
[TBL] [Abstract][Full Text] [Related]
16. Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites.
Liu K; Shi H; Xiao H; Chong AG; Bi X; Chang YT; Tan KS; Yada RY; Yao SQ
Angew Chem Int Ed Engl; 2009; 48(44):8293-7. PubMed ID: 19784986
[No Abstract] [Full Text] [Related]
17. Prediction of human immunodeficiency virus protease cleavage sites in proteins.
Chou KC
Anal Biochem; 1996 Jan; 233(1):1-14. PubMed ID: 8789141
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
19. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
[TBL] [Abstract][Full Text] [Related]
20. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]